AURINIA PHARMACEUTICALS INC (AUPH) Stock News

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

Mentions: ESPR HRTX PSTV PYXS

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.

Mentions: MYNZ

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Earnings Scheduled For February 27, 2025

Mentions: SSP CLCO CVEO DCI ...

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Aurinia Announces Board Restructuring

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Aurinia Announces 2024 Annual General Meeting Results

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Aurinia Provides Update on Proxy Statement

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference